- Home
- SHOO vs JANX Comparison
SHOO vs JANX Comparison
Compare SHOO & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOO
- JANX
- Stock Information
- Founded
- SHOO 1990
- JANX 2017
- Country
- SHOO United States
- JANX United States
- Employees
- SHOO N/A
- JANX N/A
- Industry
- SHOO Shoe Manufacturing
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- SHOO Consumer Discretionary
- JANX Health Care
- Exchange
- SHOO Nasdaq
- JANX Nasdaq
- Market Cap
- SHOO 1.9B
- JANX 1.6B
- IPO Year
- SHOO 1993
- JANX 2021
- Fundamental
- Price
- SHOO $23.11
- JANX $23.60
- Analyst Decision
- SHOO Hold
- JANX Strong Buy
- Analyst Count
- SHOO 6
- JANX 7
- Target Price
- SHOO $26.00
- JANX $94.29
- AVG Volume (30 Days)
- SHOO 1.3M
- JANX 808.2K
- Earning Date
- SHOO 07-30-2025
- JANX 08-06-2025
- Dividend Yield
- SHOO 3.63%
- JANX N/A
- EPS Growth
- SHOO N/A
- JANX N/A
- EPS
- SHOO 2.32
- JANX N/A
- Revenue
- SHOO $2,284,080,000.00
- JANX $9,336,000.00
- Revenue This Year
- SHOO $12.44
- JANX N/A
- Revenue Next Year
- SHOO $8.22
- JANX $1,470.82
- P/E Ratio
- SHOO $9.96
- JANX N/A
- Revenue Growth
- SHOO 10.34
- JANX 28.12
- 52 Week Low
- SHOO $19.05
- JANX $22.48
- 52 Week High
- SHOO $50.01
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- SHOO 42.95
- JANX 41.60
- Support Level
- SHOO $22.78
- JANX $24.45
- Resistance Level
- SHOO $24.24
- JANX $27.28
- Average True Range (ATR)
- SHOO 0.85
- JANX 1.35
- MACD
- SHOO -0.28
- JANX -0.09
- Stochastic Oscillator
- SHOO 8.71
- JANX 22.20
About SHOO Steven Madden Ltd.
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.